GSK receives marketing authorisation from the European Commission for Tafinlar™ (dabrafenib), an oral treatment for unresectable or metastatic melanoma in adult patients with a BRAF V600 mutation

GlaxoSmithKline plc announced today that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib).
Source: GSK news - Category: Pharmaceuticals Source Type: news